The U.S. Preventive Services Task Force included Exact Sciences Corp.'s (Nasdaq: EXAS) Cologuard as one of several colorectal cancer screening tests sending the stock price soaring $1.65 to $10.98.
Exact Sciences' Cologuard recommended for screening test
June 16, 2016 at 13:24 PM EDT
